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Purpose of study
Since 25-hydroxy vitamin D (25(OH)D) deficiency has
been associated with higher risk of morbidity and mor-
tality in different settings, this study examined the asso-
ciation between 25(OH)D level and disease progression
in HIV-infected patients with prospective follow-up in
the EuroSIDA study.
Methods
A group of 2000 patients were randomly selected from
those with stored samples after stratification by region.
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from stored plasma samples. The 1985 available 25(OH)
D results were stratified into tertiles. Factors associated
with 25(OH)D levels and associations of 25(OH) levels
with subsequent risk of all-cause mortality, AIDS and
non-AIDS events were analysed, using Poisson
regression.
Results
Thirty-six percent of patients had 25(OH) levels below
12 ng/ml, 31,3% between 12.1 and 20 ng/ml, and 32.7%
above 20 ng/ml. In a cross sectional analysis, older per-
sons, patients of Black ethnic origin, living outside
Southern Europe and Argentina, sampled during winter,
and infected with HIV through non-homosexual expo-
sure were at higher risk of having low 25(OH)D levels,
while patients receiving protease inhibitors were at a
lower risk. Compared to those in the lowest 25(OH)D
tertile, those in the medium and high tertiles had a sig-
nificantly lower risk of clinical progression. Adjusted
incidence rate ratios (IRR; see figure 1) for all-cause
mortality were 0.68 (95%CI : 0,47-0,99, P=0.045) and
0.56 (95%CI : 0.37-0.8, P=0.009), and for AIDS events
were 0.58 (95%CI : 0,39-0,87, P=0.0086) and 0.61 (95%
CI : 0.40-0.93, P=0.020), for the medium and high ter-
tiles, respectively. There was a non-significant reduced
incidence of non-AIDS defining events in the medium
and high tertiles, and a significant lower IRR of non-
AIDS related death in the highest 25(OH)D tertile : 0.60
(95%CI : 0.37-0.98, P=0.043).
Conclusions
This observational study demonstrated that 25(OH)D
deficiency is frequent in HIV-infected patients, and is
independently associated with a variety of outcomes,
reflected by a higher risk of mortality and AIDS events.
Whether the relationship between vitamin D deficiency
and clinical events is causal should be addressed because
of potentially major consequences in terms of public
health.
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